Data Insights
No Filter Selected
No Filter Selected
No Filter Selected
No Filter Selected
Orelabrutinib by InnoCare Pharma for Marginal Zone B-cell Lymphoma: Likelihood of Approval
Orelabrutinib is under clinical development by InnoCare Pharma and currently in Phase II for Marginal Zone B-cell Lymphoma. According to...
Orelabrutinib by InnoCare Pharma for Mantle Cell Lymphoma: Likelihood of Approval
Orelabrutinib is under clinical development by InnoCare Pharma and currently in Phase II for Mantle Cell Lymphoma. According to GlobalData,...
Orelabrutinib by InnoCare Pharma for Extranodal Marginal Zone B-Cell Lymphoma (Mucosa-Associated Lymphoid Tissue or MALT-Lymphoma): Likelihood of Approval
Orelabrutinib is under clinical development by InnoCare Pharma and currently in Phase II for Extranodal Marginal Zone B-Cell Lymphoma (Mucosa-Associated...
Orelabrutinib by InnoCare Pharma for Nodal Marginal Zone B-Cell Lymphoma: Likelihood of Approval
Orelabrutinib is under clinical development by InnoCare Pharma and currently in Phase II for Nodal Marginal Zone B-Cell Lymphoma. According...